Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Denosumab 120 mg|DRUG: Denosumab 60 mg
Sponsor: Borstkanker Onderzoek Groep
Collaborators: Amgen